MyoKardia Inc logo

MYOK - MyoKardia Inc News Story

$224.91 0.0  0.0%

Last Trade - 16/11/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6847

MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten

Sun 15th November, 2020 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201115:nGNX8Jt51F


EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session
with Simultaneous Publication in Circulation

Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure --
Significantly Reduced Hypertrophy in Patients with Hypertrophic Cardiomyopathy

BRISBANE, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:
MYOK) announced results from its cardiac magnetic resonance imaging (CMR)
substudy of mavacamten for the potential treatment of hypertrophic
cardiomyopathy (HCM) showing that 30-week treatment with mavacamten has a
favorable effect on cardiac structure, while maintaining contractile function
within the normal range. These data were shared today in an oral presentation
titled, “Mavacamten Favorably Impacts Cardiac Structure in Obstructive
Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR substudy” (Oral Session
18654), at the American Heart Association’s Scientific Sessions 2020 during
the High Profile Clinical Science in CVD session. Data from the EXPLORER-HCM
CMR substudy were also published simultaneously in Circulation.

The CMR substudy was conducted as part of MyoKardia’s pivotal Phase 3
EXPLORER-HCM clinical trial in patients with symptomatic, obstructive HCM to
assess the impact of once-daily treatment with mavacamten on parameters of
cardiac structure and function. Thirty-five patients were enrolled in the CMR
substudy and randomized to mavacamten (n=17) or placebo (n=18) and had valid
CMR assessments at day 1 and week 30 (end of treatment) which were analyzed
centrally in a blinded manner. Statistically significant changes from baseline
to Week 30 were observed in the mavacamten group vs. placebo for the primary
endpoint of left ventricular mass index (p<0.0001), as well as exploratory
endpoints of absolute intracellular myocardial mass index, maximum wall
thickness, and maximum left atrial volume index (all p<0.001 for the
difference from placebo). From baseline to Week 30, there was no worsening in
myocardial fibrosis, another common characteristic of HCM.

“Hypertrophic cardiomyopathy is defined by the thickening of the heart
muscle, so to see favorable remodeling of the heart indicating a lessening of
hypertrophy within 30-weeks of treatment is a highly encouraging finding for
the many patients struggling with HCM,” said Sara Saberi, M.D., Assistant
Professor in the Division of Cardiovascular Medicine and member of the
Inherited Cardiomyopathy Program at the University of Michigan Medical School,
and lead author on the study. “The CMR substudy is the first randomized,
controlled clinical trial of HCM patients to show that a once-daily oral
therapeutic agent can reduce left ventricular wall thickness and mass, and
positively impact several other parameters of cardiac structure and function.
Left ventricular hypertrophy and left atrial volumes in particular are
predictive of poor prognosis in HCM patients, so it will be exciting to see
how mavacamten impacts cardiac function and disease progression as we continue
to follow patients over time.”  

Changes in left ventricular hypertrophy and left atrial volumes were observed
concurrently with reductions in levels of plasma biomarkers of myocardial
stress and injury, consistent with echocardiographic observations from the
overall EXPLORER-HCM population. Importantly, the reduction in left
ventricular mass index correlated with a reduction in high-sensitivity cardiac
troponin I.  

“Data from the CMR substudy complements and extends our observations of
mavacamten’s positive benefits on cardiac function and symptom relief,
providing us with encouraging evidence that mavacamten treatment may change
the course of the adverse cardiac remodeling inherent to HCM. In directly
targeting the proteins of the heart muscle that lead to the excessive
contraction and impaired relaxation underlying HCM, we have a growing body of
data showing that mavacamten is reducing hypercontractility and hypertrophy
and reducing harm to the cardiac muscle while maintaining contractile function
within the normal range,” said Jay Edelberg, M.D., Ph.D., MyoKardia’s
Chief Medical Officer.  

As previously reported, results from EXPLORER-HCM demonstrated that patients
treated with mavacamten experienced statistically significant and clinically
meaningful improvements in symptoms, functional status and key aspects of
quality of life. In addition to meeting the primary and all secondary
endpoints, mavacamten was well tolerated with a safety profile similar to
placebo. MyoKardia plans to submit a New Drug Application for mavacamten to
the U.S. Food and Drug Administration (FDA) in the first quarter of 2021.

About EXPLORER-HCM
The EXPLORER-HCM Phase 3 trial enrolled a total of 251 patients with
symptomatic (NYHA Class II or III), obstructive hypertrophic cardiomyopathy.
All participants had measurable LVOT gradient (resting and/or provoked) ≥50
mmHg at baseline. Patients were randomized on a 1:1 basis to receive
individualized once-daily dosing of mavacamten or placebo. Patients started on
a dose of 5mg, with up to two opportunities for dose adjustments (to doses of
2.5mg – 15mg) based on a combination of residual LVOT gradient, drug plasma
concentration and left ventricular ejection fraction (LVEF) levels.

The primary endpoint for EXPLORER-HCM was a composite functional analysis
designed to capture mavacamten’s effect on both symptoms and function. The
composite functional endpoint is defined by either (1) the achievement of a
≥1.5mL/kg/min improvement in peak VO2 accompanied by an improvement of ≥1
NYHA functional class, or (2) the achievement of a ≥3.0mL/kg/min improvement
of peak VO2 with no worsening in NYHA functional class. In addition to the
endpoints reported today, the EXPLORER-HCM study also assessed mavacamten’s
effect on patient-reported outcomes, health-related quality-of-life and
symptom severity assessments, changes from baseline to Week 30 in
echocardiographic indices, circulating biomarkers, cardiac rhythm patterns and
accelerometry.

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and
developing targeted therapies for the treatment of serious cardiovascular
diseases. The company is pioneering a precision medicine approach to its
discovery and development efforts by 1) understanding the biomechanical
underpinnings of disease; 2) targeting the proteins that modulate a given
condition; 3) identifying patient populations with shared disease
characteristics; and 4) applying learnings from research and clinical studies
to inform and guide pipeline growth and product advancement. MyoKardia’s
initial focus is on small molecule therapeutics aimed at the proteins of the
heart that modulate cardiac muscle contraction to address diseases driven by
excessive contraction, impaired relaxation, or insufficient contraction. Among
its discoveries are three clinical-stage therapeutics: mavacamten (formerly
MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious
cardiovascular disease through bold and innovative science.

Forward-Looking Statements
Statements we make in this press release may include statements which are not
historical facts and are considered forward-looking within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are usually identified by
the use of words such as "anticipates," "believes," "estimates," "expects,"
"intends," "may," "plans," "projects," "seeks," "should," "will," and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act and are making this statement for
purposes of complying with those safe harbor provisions. These forward-looking
statements, including statements regarding the clinical and therapeutic
benefit and future potential of mavacamten, the ability of our long-term
studies to provide further evidence of how mavacamten impacts cardiac function
and disease progression over time, the ability of our long-term studies to
provide further evidence of mavacamten’s potential to positively impact
several other parameters of cardiac structure and function, that mavacamten
treatment may change the course of the adverse cardiac remodeling inherent to
HCM, and mavacamten’s ability to reduce harm to the cardiac muscle while
maintaining contractile function within the normal range, reflect our current
views about our plans, intentions, expectations, strategies and prospects,
which are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans, intentions,
expectations, strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance that the
plans, intentions, expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those described in the
forward-looking statements and will be affected by a variety of risks and
factors that are beyond our control including, without limitation, risks
associated with the development and regulation of our product candidates and
any ongoing effects of the COVID-19 pandemic, as well as those set forth in
our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020,
and our other filings with the SEC. Except as required by law, we assume no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.

Contacts 
Michelle Corral 
Executive Director, Corporate Communications and Investor Relations 
MyoKardia, Inc. 
650-351-4690 
ir@myokardia.com

Hannah Deresiewicz (investors) 
Stern Investor Relations, Inc. 
212-362-1200 
hannah.deresiewicz@sternir.com

Julie Normant (media)
W2O
628-213-3754
jnormart@w2ogroup.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/f2c7a5a7-d19b-4226-80bb-31c050a253fa)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.